Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Will Supreme Court Lift 'IPR Pressure' Off Biopharma?

This article was originally published in Scrip

Executive Summary

The US Supreme Court on Jan. 15 said it would hear a case to decide if the US Patent & Trademark Office (US PTO) Patent Trial and Appeal Board (PTAB) is using the proper standard when it determines the validity of a patent under so-called inter partes reviews (IPRs) and if the decisions to hold those proceedings should be judicially reviewable.

Advertisement
Advertisement
UsernamePublicRestriction

Register

SC064245

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel